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Abstract 17 
In Europe, the safety evaluation of cosmetics is based on the safety evaluation of each 18 
individual ingredient. Article 3 of the Cosmetics Regulation specifies that a cosmetic 19 
product made available on the market is to be safe for human health when used 20 
normally or under reasonably foreseeable conditions. For substances that cause some 21 
concern with respect to human health (e.g. colorants, preservatives, UV-filters), safety 22 
is evaluated at the Commission level by a scientific committee, presently called the 23 
Scientific Committee on Consumer Safety (SCCS). 24 
According to the Cosmetics Regulations, in the EU, the marketing of cosmetics 25 
products and their ingredients that have been tested on animals for most of their 26 
human health effects, including acute toxicity, is prohibited. Nevertheless, any study 27 
dating from before this prohibition took effect is accepted for the safety assessment of 28 
cosmetics ingredients. The in vitro methods reported in the dossiers summited to the 29 
SCCS are here evaluated from the published reports issued by the scientific committee 30 
of the Directorate General of Health and Consumers (DG SANCO); responsible for the 31 
safety of cosmetics ingredients. The number of studies submitted to the SCCS that do 32 
not involve animals is still low and in general the safety of cosmetics ingredients is 33 
based on in vivo studies performed before the prohibition. 34 
 35 
Highlights 36 
 SCCS safety evaluations of cosmetics ingredients are based on in vivo studies 37 
from before the animal ban.  38 
 Dermal absorption is the most common study done in vitro, although animals 39 
are also used. 40 
 Few in vitro studies of toxicokinetics were included in the dossiers. 41 
 Studies on human volunteers were also included for skin and eye irritation, 42 
dermal absorption and toxicokinetics. 43 
 44 
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 49 
1. Introduction 50 
The safety evaluation of cosmetics in Europe is based on the evaluation of each 51 
individual ingredient. Article 3 of the European Cosmetics Regulations specifies that a 52 
cosmetic product made available on the market is to be safe for human health when 53 
used normally or under reasonably foreseeable conditions. Cosmetics products have 54 
rarely been associated with serious health hazards; however, this does not mean that 55 
the use of cosmetics per se is safe. Particular attention needs to be paid to long-term 56 
safety aspects, since cosmetics products may be used extensively over a large part of 57 
the human lifespan and sensitive groups of the population such as children, old people, 58 
pregnant women, etc. may be affected. Therefore, safety-in-use for cosmetics products 59 
has been established in Europe by controlling the ingredients via their chemical 60 
structures, toxicity profiles, and patterns of exposure. 61 
The safety of those substances that cause some concern with respect to human health 62 
(e.g. colorants, preservatives,UV-filters, etc.) is evaluated at the Commission level by a 63 
scientific committee, presently called the Scientific Committee on Consumer Safety 64 
(SCCS). The substances are detailed in the Annexes of Regulation (EC) No. 65 
1223/2009, which replaced the previous Directive from 11 July 2013 onwards 66 
(European Commission, 2009). 67 
The SCCS was established in 2008 to substitute the former Scientific Committee of 68 
Consumer Products (SCCP). Before 1997, the recommendations proposed by the 69 
Scientific Committee on Cosmetology at the Commission’s request were included in 70 
EC Reports. Between 1997 and 2004, all Scientific Committee opinions were published 71 
on the Internet and can be accessed through the Committee's website. All SCCS 72 
opinions can easily be located through the substance category of the ingredient 73 
involved and the adoption date. 74 
One of the responsibilities of the SCCS is to recommend guidelines for the cosmetics 75 
and raw materials industries to develop adequate studies for the safety evaluation of 76 
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cosmetics. The SCCS evaluates the dossiers submitted by industry through the 77 
Directorate General of Health and Consumers (DG SANCO). The cosmetics 78 
ingredients evaluated by the SCCS correspond to those in the Annexes of the 79 
Regulations and to substances forbidden in Annex II, restricted substances in Annex II, 80 
and colorants, preservatives and UV-filters in Annexes IV, V and VI respectively.  81 
Determination of the toxic potential of a cosmetics product is based on a series of 82 
toxicity studies and forms part of the hazard identification. Alternative methods, 83 
replacing animal testing, have been mandatory in Europe to evaluate cosmetics 84 
ingredients since March 2013, according to a Commission Decision. However, at 85 
present, the majority of toxicological tests still involve the use of animals, as is also the 86 
case for other chemical substances. Traditionally, toxicological data that are relevant to 87 
human health have been obtained by studying the toxicological profiles on animals of 88 
the substances under consideration, using the same exposure route as that in humans 89 
(topical, oral or inhalation). 90 
When a dossier containing information on a cosmetics product is submitted to the 91 
SCCS for evaluation, the manufacturer should provide the Commission with 92 
information on: acute toxicity (if available); irritation and corrosivity to skin and eye; skin 93 
sensitisation; dermal / percutaneous absorption; repeat dose toxicity; mutagenicity / 94 
genotoxicity; carcinogenicity; reproductive toxicity; toxicokinetics; photo-induced 95 
toxicity; and human data (SCCS/1501/12). 96 
One consideration before toxicological studies are accepted for evaluation is whether 97 
the studies have been carried out according to guidelines and following Good 98 
Laboratory Practice (GLP). In some cases, this information is not present and the 99 
SCCS asks for further information before making an opinion. 100 
 101 
According to the Cosmetics Regulation (European Commission, 2009), it is prohibited 102 
in the EU to market cosmetics products and their ingredients if they have been tested 103 
on animals for most human health effects, including acute toxicity. This imposes on the 104 
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cosmetics industry the need for alternative approaches to the safety testing of the 105 
ingredients of consumer products. After a meeting of experts organised by the 106 
European Centre for the Validation of Alternative Methods (ECVAM), the alternative 107 
methods that existed at the time and had been applied to cosmetics were reviewed 108 
(Adler et al., 2011, Hartung et al., 2011). 109 
The 7th amendment to the EU Cosmetics Directive prohibits the launching of animal-110 
tested cosmetics on the European market after 2013. The European Commission 111 
invited stakeholders (industry, non-governmental organisations, EU member states and 112 
the Commission's SCCS) to identify scientific experts in five areas of toxicological: 113 
toxicokinetics, repeat dose toxicity, carcinogenicity, skin sensitisation, and reproductive 114 
toxicity. The experts selected were asked to analyse the status of and prospects for 115 
alternative methods, and to provide a scientific estimate of the time necessary to 116 
achieve full replacement of animal testing. In short, the experts confirmed that it would 117 
take at least another 7-9 years for the complete replacement of the current in vivo 118 
animal tests used for the skin sensitisation safety assessment of cosmetics ingredients 119 
for skin sensitisation. However, the experts were also of the opinion that alternative 120 
methods may provide hazard information, i.e., to differentiate between sensitisers and 121 
non-sensitisers, before 2017. This would, however, not provide complete information 122 
on what safe exposure is, because the relative potency of a sensitiser would still not be 123 
known. For toxicokinetics, the timeframe was 5-7 years to develop the models still 124 
lacking to predict lung absorption and renal/biliary excretion; and even longer to 125 
integrate the methods to fully replace animal toxicokinetic models. For the systemic 126 
toxicological endpoints of repeat dose toxicity, carcinogenicity and reproductive toxicity, 127 
the time necessary for full replacement could not even be estimated (Adler et al., 128 
2011). 129 
CAAT-Europe assembled experts from Europe, America and Asia to design a scientific 130 
roadmap for future risk assessment approaches, considering that the animal use for cosmetics 131 
testing for the European market has been banned. The key recommendations proposed 132 
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focused on improving existing methods, the combination of hazard testing and toxicokinetics 133 
predictions and the developing of integrated test strategies among others. Important points are 134 
the data quality, and the scientific background of a test method. Information from each test 135 
system should be mapped along adverse outcome pathways (Leist et al. 2014). 136 
 137 
 138 
2. Methodology 139 
The study material consisted of SCCS opinions issued between April 2008 and March 140 
2013 concerning cosmetics ingredients. No confidential data were used, as all the 141 
information came from opinions downloaded from the Committee’s website. There are 142 
different types of opinions and in some cases there are addenda to previous opinions. 143 
In this study, only full opinions were considered: addenda or specific opinions for a 144 
particular item, such as microbial resistance, were not taken into account. 145 
Each opinion was analysed with respect to each of the different sections, taking note of 146 
whether the procedure used was based on the use of animals or non-animal models. 147 
The percentage of non-animal models was compared to that of animal models and the 148 
use of human data was also noted. 149 
A total of 103 dossiers were analysed: 75 corresponded to hair dyes and 28 to other 150 
ingredients in cosmetics including UV filters, fragrances and preservatives, among 151 
others. 152 
 153 
3. Results and Discussion 154 
 155 
SCCS opinions are currently organised into hair dyes, cosmetics ingredients and 156 
nanomaterials; but over the period evaluated in the present study, the opinions were 157 
organised into fragrances, hair dyes, preservatives, UV-filters and other substances. In 158 
this paper, for comparative purposes, we distinguish between hair dyes and other 159 
ingredients, but we have also grouped the two categories together. The number of 160 
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SCCS opinions depends on the type of cosmetics; hair dyes were the most numerous 161 
with 75 substances evaluated. 162 
Studies performed on animals could be included only if they were performed before the 163 
ban on animal use in March 2009, except for repeat dose studies which were permitted 164 
until March 2013. After that date, new studies were required not to use animals. 165 
 166 
3.1. Acute toxicity 167 
Studies of acute toxicity are not always necessary for the dossiers summited to the 168 
SCCS, but they are usually included in those supplied by industrial sources and in all 169 
cases the studies were performed on laboratory animals. The oral route was the most 170 
common, but the dermal route was also used occasionallyand in a few cases 171 
information about the inhalation route was also supplied. All the accepted methods for 172 
determining acute oral toxicity are based on in vivo experiments that estimate the LD50 173 
value (i.e., the single dose of a substance that can be expected to cause death in 50% 174 
of the animals in an experimental group). Considering the prohibition on the use of 175 
animals for cosmetics ingredients and building on the results of a previous international 176 
validation study, a follow-up study was organised by the ECVAM to assess whether the 177 
3T3 Neutral Red Uptake cytotoxicity assay could identify substances not requiring 178 
classification as acute oral toxicants under the EU regulations. The assay exhibited 179 
high sensitivity (92%–96%) but relatively low specificity (40%–44%). It could thus prove 180 
to be a valuable part of an integrated testing strategy: a read-across argument or 181 
weight-of-evidence (WoE) approach to identifying non-toxic chemicals (LD50 > 2000 182 
mg/kg) (Prieto et al., 2013). In the dossiers supplied by industry sources for SCCS 183 
evaluation over the period 2009-2013, no assays to predict acute toxicity were 184 
performed in vitro. 185 
 186 
 187 
 188 
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3.2. Eye irritation 189 
Eye irritation is one of the classic studies performed on animals, usually rabbits, as 190 
reported many years ago (Draize et al., 1944). The method has been highly 191 
controversial and much effort has gone into developing alternative methods (Vinardell 192 
and Mitjans, 2008). However, the validated in vitro methods focus on distinguishing 193 
corrosive and more irritant chemicals from non-irritants, and they do not make 194 
categorisation possible, in contrast to the in vivo method. In the dossiers submitted to 195 
the SCCS, nearly all the studies were performed on albino rabbits; only a few used in 196 
vitro methods. The majority of the in vivo studies performed on rabbits followed the 197 
OECD guidelines, which were adopted in 1981 and updated successively in 1987, 198 
2002 and then recently in 2012 (OECD, 2012). However, some studies adhered to no 199 
specific guidelines and were not even performed under GLP conditions; some used 200 
guinea pigs as the animal model.  201 
Among the in vitro methods reported in the dossiers related to different ingredients, we 202 
found the isolated chicken eye (ICE) and the bovine corneal opacity and permeability 203 
(BCOP) tests; two validated methods that appear in the OECD guidelines (OECD, 204 
2013a,b). These are in vitro tests used to identify chemicals (individual substances or 205 
mixtures) as either: 1) causing "serious eye damage" (category 1 of the Globally 206 
Harmonised System for the Classification and Labelling of Chemicals (GHS)); or 2) not 207 
requiring classification for eye irritation or serious eye damage according to the GHS. 208 
Other methods that are used include the Het-Cam: a method that has not been 209 
validated but which is very widely used by the cosmetics industry due to its low cost; 210 
and neutral red uptake in cell cultures (Spielmann et al., 1996). When comparing the 211 
results for hair dyes with those for other ingredients, we observed that in the former 212 
case there were no studies on human volunteers whereas in the latter case human 213 
studies represented 9% of the total. When we considered all the ingredients together, 214 
the percentage of human studies was just 3% (Figure 1). The use of human volunteers 215 
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in studies of eye irritation is not considered ethical by the SCCS, as indicated in many 216 
opinions.   217 
 218 
 219 
 220 
 221 
 222 
 223 
 224 
 225 
Figure 1. Percentage of eye irritation studies performed in vivo, in vitro and on human 226 
volunteers. 227 
 228 
The need for alternative approaches to replace the in vivo Draize rabbit eye test for the 229 
evaluation of the eye irritation of cosmetics has been recognised by the cosmetics 230 
industry for many years. There has been extensive research into the development of 231 
different assays, some of which have been formally validated; but no single in vitro 232 
assay has been validated as a full replacement for the Draize rabbit eye test. Although 233 
not formally validated, several other in vitro models have been used for over a decade 234 
by the cosmetics industry as valuable tools in a WoE approach to the safety 235 
assessment of ingredients and finished products. Cosmetic Europa, formerly COLIPA, 236 
organised a scientific meeting in 2008 to review the use of alternative approaches and 237 
to set up a decision-tree approach for their integration into tiered testing strategies for 238 
the hazard and safety assessment of cosmetics ingredients and their use in products 239 
(McNamee et al., 2009). The conclusion was that confidence in the evaluation of eye 240 
irritation potential is increased through the use of combinations of assays to obtain a 241 
classification of the irritancy potential (from non-irritant to severe). A combination was 242 
proposed of both recognised accepted and non-validated assays, together with all 243 
87% 
3% 
10% 
Eye irritation 
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other available information, in a tiered approach based on a WoE evaluation of eye 244 
irritation. General acceptance of such an approach is necessary for animal studies to 245 
be replaced by it. 246 
 247 
3.3. Skin irritation 248 
In the case of skin irritation, the accepted method was adopted in 1981 and updated in 249 
2002 (OECD, 2002). The method is based on the use of rabbit, in a way similar to that 250 
used in the Draize eye test, and this was the most commonly used method in these 251 
evaluations. However, other species such as guinea pig or mouse were used to a 252 
lesser extent for the evaluation of hair dyes. In the case of other substances, the use of 253 
human volunteers was observed. The use of in vitro methods has been very limited: to 254 
TER (rat skin transcutaneous electrical resistance test) and to the use of reconstructed 255 
epidermis models. The percentage of the different methods used to assay all the 256 
ingredients is shown in Figure 2. The use of in vitro methods was even less common 257 
than the use of human volunteers. 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
Figure 2. Percentage of skin irritation studies performed in vivo, in vitro and on human 268 
volunteers. 269 
 270 
 271 
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A number of in vitro skin irritation tests have been officially validated and are accepted 272 
in the OECD guidelines such as OECD439 (OECD, 2013c). The methods are based on 273 
reconstructed human epidermis. Taking the EpiSkinTM method as an example, the 274 
SCCS expressed concerns over potential interference with colour formation from 275 
reducing substances, hair dyes and colourants (SCCP/1145/07). After studying 276 
additional data supplied by an industry source, the SCCS expressed the opinion that 277 
the modified EpiSkin™ method did not sufficiently show that the 3-(4,5)-dimethyl-2-278 
thiazolyl-2,5-dimethyl-2Htetrazolium bromide (MTT) test could be used as a suitable 279 
endpoint to test colour ingredients/hair dyes for their potential skin irritation. A different 280 
endpoint, not involving optical density quantification, should be sought 281 
[SCCS/1392/10]. 282 
For skin corrosion testing, at present 5 validated in vitro alternatives have been 283 
included in the Regulations: the TER (OECD, 2013d) and tests on reconstructed 284 
human epidermis (EpiSkin™, EpiDerm™, SkinEthic™ and EST-1000 (epidermal skin 285 
test-1000) (OECD, 2013e). 286 
Similarly to the case of eye irritation, Cosmetic Europe (formerly COLIPA) has devised 287 
a decision tree. One of the conclusions of the COLIPA workshop and Project Team 288 
Safety Assessment 2009/2013, was that the good correlation between in vitro and in 289 
vivo skin irritation assays, together with the substantial in-house experience with the 290 
former, allows for confidence in the outcomes of these assays, such that in-house 291 
safety assessments of new products can be made without the use of animal testing. A 292 
decision tree for hazard assessment and classification, using a WoE approach 293 
throughout, involves stepwise evaluation of: firstly, physicochemical characteristics, 294 
(Q)SAR and existing data, to identify and rule out corrosive chemicals from further 295 
testing; secondly, in vitro corrosivity; and finally, in vitro irritation, to distinguish between 296 
irritants and non-irritants. Once a chemical has been classified as corrosive, irritant or 297 
non-irritant, its safety assessment can then be evaluated using a second decision tree 298 
approach. Corrosive chemicals should be tested in an in vitro corrosivity test at the use 299 
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concentration and, if shown to be non-corrosive, tested for irritation using an RHE in 300 
vitro irritation model. Chemicals classed as irritants can be retested at the usage 301 
concentration, since they may not be irritants at lower concentrations or when used in 302 
the final formulation. Human confirmatory testing of the formulation is only carried out 303 
on a case-by-case basis. In conclusion, the evaluation of the skin irritation potential of 304 
new chemicals to be used in cosmetics can be confidently accomplished using only 305 
alternative methods (Macfarlane et al., 2009). 306 
 307 
3.4. Skin sensitisation 308 
For skin sensitisation, the studies were mostly performed in vivo (81%) and a small 309 
percentage on humans using the patch test method (Figure 3). 310 
 311 
 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
 320 
Figure 3. Percentage of sensitisation studies performed in vivo and on human 321 
volunteers. 322 
 323 
Officially accepted animal testing methods for assessing skin sensitisation potential 324 
include: the mouse Local Lymph Node Assay (LLNA) and its non-radioactive 325 
modifications (LLNA-DA and the LLNA-BrdU Elisa) (OECD, 2010); the Guinea Pig 326 
Maximisation Test (GPMT) by Magnusson & Kligman; and the Buehler occluded patch 327 
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test in the guinea pig (OECD, 1992). The mouse and guinea pig methods differ with 328 
respect to the endpoints used: whereas the mouse LLNA measures the responses 329 
provoked during the induction of sensitisation, the two guinea pig tests measure 330 
challenge-induced elicitation reactions in previously sensitised animals. The Buehler 331 
method is less sensitive than the GPMT and scientific justification should be given if the 332 
Buehler test is used [SCCS/1501/12]. The mouse LLNA was used more than the 333 
methods based on guinea pigs (Figure 4). 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
Figure 4. Percentage of sensitisation studies performed on mice and guinea pigs. 343 
 344 
The LLNA is considered a reduction and refinement method compared to the traditional 345 
guinea pig tests since it provides advantages in terms of animal welfare, but it cannot 346 
more be used for evaluation of ingredients in cosmetics. 347 
The most commonly used in vivo method was the LLNA. The basic principle underlying 348 
the mouse LLNA is that sensitisers induce a primary proliferation of lymphocytes in the 349 
auricular lymph nodes that drain the chemical application site. This proliferation is 350 
proportional to the dose applied and provides a measure of sensitisation. 351 
As opposed to the skin or eye irritation studies, animal sensitisation studies were 352 
permitted until March 2013 under European legislation, because they correspond to 353 
repeat dose toxicity. Of the studies presented, none were in vitro; nevertheless, there 354 
are two validated methods that are currently in the final phase of OECD approval.  355 
59% 
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Those two methods are the Direct Peptide Reactivity Assay (DPRA) (Gerberick et al., 356 
2004, 2007) and KeratinoSens™ (Natsch et al., 2014; Delaine et al., 2011). The DPRA 357 
addresses the process of haptenation, i.e., the covalent binding of low-molecular-358 
weight substances (haptens) to skin proteins, which is considered to be the molecular 359 
initiating event of skin sensitisation. KeratinoSens™ addresses the activation of the 360 
antioxidant/electrophile response element (ARE)-dependent pathway in keratinocytes; 361 
a biological mechanism covered by the second key event of skin sensitisation. Both 362 
test methods provide mechanistic information considered relevant for the assessment 363 
of the skin sensitisation potential of chemicals. 364 
The human studies were performed by old methods (Marzulli and Maibach, 1986; 365 
Kligman, 1966; Kligman and Epstein, 1975) based on the maximisation response in 366 
volunteers. The human repeat insult patch test (HRIPT) consists of 2 phases, or 367 
sometimes 3. Phase I is the induction phase, where the product is applied to the skin 9 368 
times over the course of 3 weeks. This is followed by a two-week rest period, after 369 
which the skin is exposed to the product again in phase II: the elicitation phase. A 370 
response in phase II is usually allergic in nature and phase III is used to verify and 371 
better define the reaction. The different methods available have different application 372 
phases, but the resulting predictions of allergy and irritation response are the scientific 373 
goals. Use of the HRIPT is considered unethical by the SCCS.  374 
 375 
3.5. Dermal absorption 376 
Dermal absorption is a well-established in vitro method that is described in the OECD 377 
guidelines and there is a special SCCS memorandum that describes the procedure 378 
(SCCS/1358/10). Despite the existence of an in vitro protocol, some studies were 379 
performed on animals and human volunteers (Figure 5). 380 
The in vivo studies were performed on rats, but in some cases rabbits were also used. 381 
The in vitro method can use skin from humans or pigs, according to the SCCS 382 
recommendations. Human skin is the better choice but is not always readily available.  383 
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 384 
 385 
 386 
 387 
 388 
 389 
 390 
 391 
 392 
Figure 5. Percentage of dermal absorption studies performed in vitro, in vivo and on 393 
human volunteers. 394 
 395 
Alternatively, pig skin may be used as it shares essential permeation characteristics 396 
with human skin. However, 12 studies (11.65%) used rat skin, despite high levels of 397 
absorption having been demonstrated for this skin; it is some 2 to 10 times more 398 
permeable than human skin due to differences in the thickness of the epidermis (Ross 399 
et al., 2000). 400 
Another option is to use cultured or reconstructed human skin models; but such 401 
systems are not yet recommended for in vitro testing, on the basis of an insufficient 402 
barrier function (Bouwstra et al., 2008). Some studies propose the use of a fully 403 
differentiated human skin trilayer that could have multiple applications such as in vitro 404 
drug absorption tests and regenerative therapies (Monfort et al., 2013); but such 405 
engineered skin has not yet been validated. 406 
 407 
3.6. Genotoxicity 408 
In the assessment of genotoxicity there are many in vitro methods that provide 409 
information on three major genetic endpoints: mutagenicity at a gene level, 410 
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chromosome breakage and/or rearrangements (clastogenicity), and numerical 411 
chromosome aberrations (aneugenicity) (Pfuhler et al. 2010).  412 
Due to the diverse nature of the mechanisms involved in genotoxicity, it is known that 413 
no single test can detect all genotoxic effects. In this sense, the SCCS recommended 414 
recently the combination of two assays the Bacterial reverse Mutation Test (OECD, 415 
1997) as a test covering gene mutations and In vitro Micronucleus Test (OECD 2014) 416 
as a test for both structural (clastogenicity) and numerical (aneugenicity) chromosome 417 
aberrations. The combination of these two assays would cover the three genotoxicity 418 
endpoints described above, as the bacterial test detects gene mutations and the in vitro 419 
micronucleus assay detects both structural and numerical chromosome aberrations. 420 
Except for special cases for which the Ames test is not suitable, the SCCS 421 
recommends the combination of the two assays for the base level testing of cosmetic 422 
substances (SCCS/1532/14).  423 
These two assays have been used for evaluating genotoxicity in all the dossiers 424 
evaluated by the SCCS, together with other in vitro and in vivo methods, the last 425 
performed before the ban for animals use. 426 
 427 
3.7. Carcinogenicity 428 
Studies of carcinogenicity were not included in all the dossiers. Of the dossiers 429 
evaluated, only 37 included studies of carcinogenesis; mostly in vivo, with only 22% 430 
performed in vitro (Figure 6).  431 
The in vivo studies were performed on mice, rats and hamsters; and by different 432 
routes: oral, dermal and inhalation (Mallye et al., 2001). In most cases the method did 433 
not follow any guidelines, despite the corresponding OECD Guideline being adopted in 434 
1981 and recently revised (OECD, 2009). 435 
The in vitro studies correspond to the in vitro cell transformation assay (CTA) in 436 
BALB/c3T3 (Mascolo et al., 2010; Matthew et al., 1993) and the Syrian hamster 437 
embryo cell (SHE) assay (Jones et al., 1988). 438 
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 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
Figure 6 . Percentage of carcinogenicity studies performed in vivo and in vitro.  449 
 450 
The BALB/c 3T3 model represents one of the best-known CTAs and is regarded as a 451 
useful tool to screen single chemicals or complex mixtures for carcinogenicity. Of the in 452 
vitro testing methods, CTAs appear to be one of the most suitable tools to predict the 453 
carcinogenic properties of chemicals (Lilienblum et al., 2008). Matthews et al. (1993) 454 
published a comprehensive review comparing the results obtained for 147 compounds 455 
in the BALB/c3T3 transformation test with those from animal bioassays; a good 456 
correlation was shown with good sensitivity but poor specificity. 457 
SHE cell transformation has been used almost since it was first reported as an in vitro 458 
test to determine potential carcinogenicity of chemical/physical agents. Many groups 459 
worldwide have used this assay to study the carcinogenic capacity of a wide variety of 460 
chemical/physical agents and several inter-laboratory studies have been conducted to 461 
evaluate the assay (Isfort, 1996).  462 
These methods are not yet accepted, but there are some validation studies (Corvi et 463 
al., 2012; Pant et al., 2012). Drafts of the guideline protocols are available online: 464 
http://www.oecd.org/env/ehs/testing/Draft%2017%20October%202012.pdf. 465 
 466 
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3.8. Toxicokinetic studies 467 
The Toxicokinetic studies included different procedures and were usually performed in 468 
vivo on different animals or humans (Fig 7).  469 
 470 
 471 
 472 
 473 
 474 
 475 
 476 
 477 
 478 
 479 
Figure 7. Percentage of toxicokinetic studies performed in vivo, in vitro or on human 480 
volunteers. 481 
 482 
In vitro methods to study these phenomena should be based on different aspects of the 483 
process (absorption, metabolism, etc.). 484 
The process of absorption has been studied in the TC-7 cell line, which is a clone of 485 
CaCo-2 cells, usually used in in vitro studies of oral absorption (Gres et al., 1998). In 486 
total, 10 hair dyes were studied. A study sponsored by the ECVAM evaluated the 487 
reproducibility (between-laboratory and within-laboratory variability) and the predictive 488 
capacity of two in vitro cellular systems—the Caco-2/ATCC parental cell line and the 489 
Caco-2/TC7 clone—at estimating the oral fraction absorbed (Fa) in humans (Prieto et 490 
al., 2010). The study concluded that good estimations of human Fa for five well-491 
absorbed compounds was demonstrated; while moderately and poorly absorbed 492 
compounds were overestimated.  493 
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In the studies presented to assess the toxicokinetic effects of cosmetics ingredients, 494 
there were studies of metabolism in hepatocytes obtained from humans, rats or mice. 495 
These isolated cells (Klieber et al., 2010) or 3D models (Godoy et al., 2013) have been 496 
used in many studies to demonstrate effects on metabolism in vitro. Some studies of 497 
metabolism have been performed on keratinocytes or reconstructed epidermis. The 498 
use of reconstructed epidermis has been demonstrated to be a good strategy for 499 
studying metabolism in vitro (Hewitt et al., 2013; Götz et al., 2012a,b). 500 
 501 
3.9. Phototoxicity 502 
Phototoxicity studies were carried out on products that are especially exposed to solar 503 
radiation, such as UV filters, but also on some other products, such as some hair dyes, 504 
preservatives, etc. In all, only 35 of the products were studied for phototoxicity. One 505 
third of the studies were in vitro and nearly half were in vivo: the rest were on human 506 
volunteers (Figure 8). 507 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
Figure 8. Percentage of phototoxicity studies performed in vivo, in vitro and on human 518 
volunteers. 519 
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Some studies of phototoxicity are related to the photomutagenicity response or 522 
photoallergy, rather than phototoxicity. All the hair dyes studied used in vivo studies in 523 
guinea pigs. The studies on human volunteers corresponded to UV-filters, and some 524 
preservatives, fragrances and other substances. In total, 9 substances were assessed 525 
in humans. 526 
Only five studies corresponded to the validated and accepted method of 3T3-NRU 527 
phototoxicity (ECVAM, 1998; Spielmann et al., 1998; Gaspar, 2013; Ceridono et al., 528 
2013). It is surprising that so few studies were performed using this method, 529 
considering it was the first validated in vitro method to be accepted by the OECD 530 
(OECD, 2004). 531 
A recent study has established a non-animal photosafety assessment approach for 532 
cosmetics using in vitro photochemical and photobiochemical screening systems The 533 
photochemical properties were assessed in by UV/VIS spectral analysis, reactive 534 
oxygen species (ROS) assay and 3T3 neutral red uptake phototoxicity testing (3T3 535 
NRU PT). These in vitro screening systems individually provide false predictions; 536 
however, a systematic tiered approach using these assays was proposed to provide 537 
photosafety assessment without any false-negatives (Onoue et al. 2013). 538 
 539 
Conclusions 540 
The toxicological studies of new cosmetics ingredients should at present be in vitro. 541 
However, safety evaluation can be based on in vivo studies performed before the 542 
European ban on the use of animals came into effect. The evaluations of different 543 
cosmetics ingredients performed by the SCCS are mostly based on in vivo studies from 544 
before the ban. At the moment, the total number of in vitro studies is small compared to 545 
that of studies on laboratory animals. We believe the near future will see an increase in 546 
the use of in vitro methods. There are some validated and accepted methods, but there 547 
are not methods for all the studies required; there are no validated and accepted 548 
methods for repeat dose toxicity, toxicokinetics and others.  549 
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Legends to figures 762 
Figure 1. Percentage of eye irritation studies performed in vivo, in vitro and on human 763 
volunteers. 764 
Figure 2. Percentage of skin irritation studies performed in vivo, in vitro and on human 765 
volunteers. 766 
Figure 3. Percentage of sensitisation studies performed in vivo and on human 767 
volunteers. 768 
Figure 4. Percentage of sensitisation studies performed on mice and guinea pigs. 769 
Figure 5. Percentage of dermal absorption studies performed in vitro, in vivo and on 770 
human volunteers. 771 
Figure 6 . Percentage of carcinogenicity studies performed in vivo and in vitro.  772 
Figure 7. Percentage of toxicokinetic studies performed in vivo, in vitro or on human 773 
volunteers. 774 
Figure 8. Percentage of phototoxicity studies performed in vivo, in vitro and on human 775 
volunteers. 776 
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